AU2003219847A1 - Methods and compositions for reversibly controlling expression of target genes in cells - Google Patents

Methods and compositions for reversibly controlling expression of target genes in cells

Info

Publication number
AU2003219847A1
AU2003219847A1 AU2003219847A AU2003219847A AU2003219847A1 AU 2003219847 A1 AU2003219847 A1 AU 2003219847A1 AU 2003219847 A AU2003219847 A AU 2003219847A AU 2003219847 A AU2003219847 A AU 2003219847A AU 2003219847 A1 AU2003219847 A1 AU 2003219847A1
Authority
AU
Australia
Prior art keywords
compositions
cells
methods
target genes
controlling expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003219847A
Inventor
Kasirajan Ayyanathan
Frank J. Rauscher
David C. Schultz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wistar Institute of Anatomy and Biology
Original Assignee
Wistar Institute of Anatomy and Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Institute of Anatomy and Biology filed Critical Wistar Institute of Anatomy and Biology
Publication of AU2003219847A1 publication Critical patent/AU2003219847A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU2003219847A 2002-02-21 2003-02-20 Methods and compositions for reversibly controlling expression of target genes in cells Abandoned AU2003219847A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35859902P 2002-02-21 2002-02-21
US60/358,599 2002-02-21
PCT/US2003/005347 WO2003072788A1 (en) 2002-02-21 2003-02-20 Methods and compositions for reversibly controlling expression of target genes in cells

Publications (1)

Publication Number Publication Date
AU2003219847A1 true AU2003219847A1 (en) 2003-09-09

Family

ID=27765968

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003219847A Abandoned AU2003219847A1 (en) 2002-02-21 2003-02-20 Methods and compositions for reversibly controlling expression of target genes in cells

Country Status (2)

Country Link
AU (1) AU2003219847A1 (en)
WO (1) WO2003072788A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
EP1412493B1 (en) 2001-08-02 2011-10-05 Institut Clayton De La Recherche Methods and compositions relating to improved lentiviral vector production systems
EP1438075A4 (en) 2001-10-02 2006-04-19 Inst Clayton De La Rech Methods and compositions relating to restricted expression lentiviral vectors and their applications
WO2011040887A1 (en) * 2009-09-30 2011-04-07 Agency For Science, Technology And Research A nuclear receptor and mutant thereof and the use of the same in the reprogramming of cells
WO2013163628A2 (en) 2012-04-27 2013-10-31 Duke University Genetic correction of mutated genes
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
CN110540991B (en) * 2013-03-15 2023-10-24 通用医疗公司 Enhancement of specificity of RNA-guided genome editing using truncated guide RNA (tru-gRNA)
WO2014204578A1 (en) 2013-06-21 2014-12-24 The General Hospital Corporation Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
AU2014346559B2 (en) 2013-11-07 2020-07-09 Editas Medicine,Inc. CRISPR-related methods and compositions with governing gRNAs
EP3957735A1 (en) 2014-03-05 2022-02-23 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
US11339437B2 (en) 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
WO2015138510A1 (en) 2014-03-10 2015-09-17 Editas Medicine., Inc. Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
EP3981876A1 (en) 2014-03-26 2022-04-13 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease
GB201418965D0 (en) * 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
CN107690480B (en) 2015-04-24 2022-03-22 爱迪塔斯医药公司 Evaluation of CAS9 molecule/guide RNA molecule complexes
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US11970710B2 (en) 2015-10-13 2024-04-30 Duke University Genome engineering with Type I CRISPR systems in eukaryotic cells
WO2017165862A1 (en) 2016-03-25 2017-09-28 Editas Medicine, Inc. Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
AU2017305404B2 (en) 2016-08-02 2023-11-30 Editas Medicine, Inc. Compositions and methods for treating CEP290 associated disease
EP3596217A1 (en) 2017-03-14 2020-01-22 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
US11667677B2 (en) 2017-04-21 2023-06-06 The General Hospital Corporation Inducible, tunable, and multiplex human gene regulation using CRISPR-Cpf1
EP3622070A2 (en) 2017-05-10 2020-03-18 Editas Medicine, Inc. Crispr/rna-guided nuclease systems and methods
WO2019204766A1 (en) 2018-04-19 2019-10-24 The Regents Of The University Of California Compositions and methods for gene editing
KR20220040476A (en) * 2019-08-01 2022-03-30 메모리얼 슬로안 케터링 캔서 센터 Cells for improved immunotherapy and uses thereof
CN117143220B (en) * 2023-10-31 2024-02-13 深圳市帝迈生物技术有限公司 TRIM28 protein truncated body, TRIM28 protein mutant and kit for screening breast cancer markers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002219992A1 (en) * 2000-12-01 2002-06-11 Sangamo Biosciences, Inc. Targeted regulation of gene expression

Also Published As

Publication number Publication date
WO2003072788A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
AU2003219847A1 (en) Methods and compositions for reversibly controlling expression of target genes in cells
AU2003225791A1 (en) Methods and compositions for directing cells to target organs
AU2003216058A1 (en) Mammalian neural stem cells, compositions and uses thereof
AU2003219760A1 (en) Optimization of gene sequences of virus-like particles for expression in insect cells
AU2003256249A8 (en) Compositions and methods for suppressing eukaryotic gene expression
AU1201600A (en) Controlling gene expression in living cells
AU2003239129A1 (en) Methods and compositions for dna manipulation
AU2003288686A1 (en) Compositions and systems for the regulation of genes
AU2003241313A1 (en) Compositions and methods for stem cell delivery
AU2003260351A1 (en) Cell culture insert
AU2003290432A1 (en) T cell activating gene
AU2002348947A1 (en) Compositions and methods for amplification of human stem cells
AU2003216840A1 (en) Transdifferentiation of cells and tissues
AU2003240281A1 (en) Cell targeting methods and compositions
AU2003901316A0 (en) Regulation of cell surface proteins
EP1575512A3 (en) Methods and compositions for prostate epithelial cell differentiation
WO2004081030A8 (en) Peptides selectively lethal to malignant and transformed mammalian cells
AU2003251531A1 (en) Compositions and methods relating to breast specific genes and proteins
AU2002340898A1 (en) Design of artificial genes for use as controls in gene expression analysis systems
AU2003275548A1 (en) Culture method of controlling the composition of copolymer polyester
AU2003302927A1 (en) Genetic modification of carotenoid content in plants
AU2003299491A1 (en) Fagopyritol synthase genes and uses thereof
AU2003208843A1 (en) Method of single cell cloning in eukaryotic cell culture
AU2003290463A1 (en) Plant genes and their use in controlling abcission in plants
AU2003242960A1 (en) Methods and compositions for regulation of mammalian hair growth

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase